

Real-Life Oncology

Case-Based Discussions on the Biopsychosocial Management of Patients with Breast Cancer



Select Publications

ALTT0 (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study; BIG 2-06/N063D. **NCT00490139**

An open-label study of trastuzumab-MCC-DM1 (T-DM1) vs capecitabine + lapatinib in patients with HER2-positive locally advanced or metastatic breast cancer (EMILIA). **NCT00829166**

Baselga J et al. **First results of the NeoALTT0 trial (BIG 01-06/EGF 106903): A Phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer.** San Antonio Breast Cancer Symposium 2010;Abstract S3-3.

Belavic JM. **Denosumab (Prolia): A new option in the treatment of osteoporosis.** *Nurse Pract* 2011;36(1):11-2. No abstract available

Blowers E, Hall K. **Adverse events in bevacizumab and chemotherapy: Patient management.** *Br J Nurs* 2009;18(7):424-8. **Abstract**

Brem S, Kumar NB. **Management of treatment-related symptoms in patients with breast cancer.** *Clin J Oncol Nurs* 2011;15(1):63-71. **Abstract**

Frankel C, Palmieri FM. **Lapatinib side-effect management.** *Clin J Oncol Nurs* 2010;14(2):223-33. **Abstract**

Gianni L et al. **Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized Phase II study ('NeoSphere').** San Antonio Breast Cancer Symposium 2010;Abstract S3-2.

Hurtig J. **Managing patients with advanced and metastatic breast cancer.** *Clin J Oncol Nurs* 2010;14(3):313-23. **Abstract**

Mackey JR. **Poster discussion: Metastatic breast cancer erbB/HER directed therapies.** Breast Cancer Symposium 2009. **Discussant**

Mayer M. **Lessons learned from the metastatic breast cancer community.** *Semin Oncol Nurs* 2010;26(3):195-202. **Abstract**

Montgomery M, McCrone SH. **Psychological distress associated with the diagnostic phase for suspected breast cancer: Systematic review.** *J Adv Nurs* 2010;66(11):2372-90. **Abstract**

Moss LS et al. **Trastuzumab-induced cardiotoxicity.** *Oncol Nurs Forum* 2009;36(6):676-85. **Abstract**

Onishi T et al. **Future directions of bone-targeted therapy for metastatic breast cancer.** *Nat Rev Clin Oncol* 2010;7(11):641-51. **Abstract**

Palmieri FM et al. **Adjuvant trastuzumab for HER2-positive early breast cancer.** *Clin J Oncol Nurs* 2010;14(3):326-36. **Abstract**

Robertson FM et al. **Inflammatory breast cancer: The disease, the biology, the treatment.** *CA Cancer J Clin* 2010;60(6):351-75. **Abstract**

Rosedale M, Fu MR. **Confronting the unexpected: Temporal, situational, and attributive dimensions of distressing symptom experience for breast cancer survivors.** *Oncol Nurs Forum* 2010;37(1):E28-33. **Abstract**

Stopeck AT et al. **Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study.** *J Clin Oncol* 2010;28(35):5132-9. **Abstract**

Study of suitable schedule of docetaxel, anthracycline and cyclophosphamide in adjuvant therapy of breast cancer. **NCT00525642**

Untch M et al. **Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: Primary efficacy endpoint analysis of the GEPARQUINTO STUDY (GBG 44).** San Antonio Breast Cancer Symposium 2010; **Abstract S3-1.**

Wilton JM. **Denosumab: New horizons in the treatment of osteoporosis.** *Nurs Womens Health* 2011;15(3):249-52. No abstract available